Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
World game at war: why some European nations have threatened a World Cup boycott 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Dublin, April 13, 2018 -- The "Acute Decompensated Heart Failure Forecast and Market Analysis to 2034" report has been added to ResearchAndMarkets.com's offering.
Acute decompensated heart failure (ADHF) is defined as the sudden worsening of heart failure symptoms (mainly edema, dyspnea, and fatigue), which results in severe respiratory distress. ADHF is categorized into hemodynamic stages based on the degree of perfusion and pulmonary capillary wedge pressure. Despite improvements in treatment, ADHF is a burdensome disease associated with high hospitalization and mortality rates in the elderly population.
Recent events and opinion
- ADHF treatment is focused on hemodynamic stabilization and alleviation of symptoms.
- The author estimates that in 2016, there were 1.2 million diagnosed incident cases of ADHF in the US, Japan, and five major EU markets.
- Natrecor and Simdax have had limited success in the highly genericized ADHF market.
- Discontinuations of ularitide and Reasanz have left the ADHF pipeline bare.
Key Topics Covered:
1 Treatment: Acute Decompensated Heart Failure (Published on 19 January 2018)
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Current Treatment Options
- Prescribing Trends
2 Epidemiology: Acute Decompensated Heart Failure (Published on 18 January 2018)
- Executive Summary
- Disease Background
- Sources And Methodology
- Forecast
- Epidemiologist Insight
- Strengths And Limitations
- Bibliography
- Appendix: Additional Sources
3 Marketed Drugs: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)
- Executive Summary
- Product Overview
- Diuretics
- Vasodilators
- Inotropic Agents
- Other Drug Classes
- Product Profile: NATRECOR
- Product Profile: SIMDAX
4 Pipeline: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)
- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Product Profile (Late Stage): BMS-986231
For more information about this report visit https://www.researchandmarkets.com/research/gn65vq/world_acute?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology
